In vivo evaluation of [123I]-4-iodo-N-(4-(4-(2-methoxyphenyl)- piperazin-1-yl)butyl)-benzamide: A potential sigma receptor ligand for SPECT studies

Nuclear Medicine and Biology

Volumn 32, Issue 2, 2005, Pages 193-200

  Staelens, Ludovicus ^a   Oltenfreiter, Ruth ^a   Dumont, Filip ^a   Waterhouse, Rikki N ^b   Vandenbulcke, Katia ^a   Blanckaert, Peter ^a   Dierckx, Rudi A ^c   Slegers, Guido ^a  

^a GHENT UNIVERSITY   (Belgium)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

123I; Dopamine D3 receptors SPECT; Sigma receptors

Indexed keywords

4 IODO N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL]BENZAMIDE I 123; RADIOLIGAND; SIGMA OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG; 4 IODO N (4 (4 (2 METHOXYPHENYL) PIPERAZIN 1 YL)BUTYL) BENZAMIDE; 4-IODO-N-(4-(4-(2-METHOXYPHENYL)-PIPERAZIN-1-YL)BUTYL)-BENZAMIDE; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG UPTAKE; IMAGING SYSTEM; IN VIVO STUDY; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; PROTEIN LOCALIZATION; RABBIT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; ANTIBODY SPECIFICITY; BRAIN; COMPARATIVE STUDY; FEASIBILITY STUDY; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; SCINTISCANNING; SPECIES DIFFERENCE; TISSUE DISTRIBUTION;

ANIMALS; BENZAMIDES; BRAIN; FEASIBILITY STUDIES; MALE; METABOLIC CLEARANCE RATE; MICE; ORGAN SPECIFICITY; PIPERAZINES; RABBITS; RADIOPHARMACEUTICALS; RECEPTORS, SIGMA; SPECIES SPECIFICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 13844305877     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2004.09.007     Document Type: Article

References (8)

1. W.R. Martin, C.E. Eades, J.A. Thompson, R.E. Huppler, and P.E. Gilbert The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog J. Pharmacol. Exp. Ther. 197 1976 517 532
2. R. Quirion, R. Chicheportiche, P.C. Contreras, K.M. Johnson, D. Lodge, and S.W. Tam Classification and nomenclature of phencyclidine and sigma receptor sites Trends Neurosci. 10 11 1987 444 446
3. W.D. Bowen Sigma receptors: recent advances and new clinical potentials Pharm. Acta Helv. 74 2000 211 218
4. B.J. Vilner, C.S. John, and W.D. Bowen Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines Cancer Res. 55 2 1995 408 413
5. R.R. Matsumoto, Y. Liu, M. Lerner, E.W. Howard, and D.J. Brackett Receptors: potential medications development target for anti-cocaine agents Eur. J. Pharmacol. 469 1-3 2003 1 12
6. 3 receptor Bioorg. Med. Chem. Lett. 5 1995 219 222
7. 18F]-1-(3-Fluoropropyl)-4-(4-cyanophenoxymethyl)-piperidine: a potential sigma-1 receptor radioligand for PET J. Labelled Comp. Radiopharm. 38 9 1996 785 794
8. 3 antagonist for SPECT studies J. Labelled Comp. Radiopharm. 46 2003 297 305